Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New MRI scans reveal hidden brain changes after first MS symptoms

NCT ID NCT03692975

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study used a special MRI technique to look at tiny brain changes in people who recently had a first episode of symptoms that could lead to multiple sclerosis (MS). Researchers compared 84 participants (patients and healthy controls) to see if early memory problems are linked to microscopic damage in the hippocampus, a brain area key for memory. The goal was to better understand how MS starts, not to test a treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

84 people

The number who actually took part.

Started

Feb 2019

Finished

Feb 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * \- PATIENTS: * Men and Women, * Age 18-60 years, * Native French language, * Clinically isolated neurological syndrome (CIS) compatible with a demyelinating inflammatory episode within the central nervous system, potentially beginning multiple sclerosis (MS) whatever the mode of presentation, * Between 60 and 180 days from the onset, * At least two clinically silent lesions on their T2-weighted brain or spinal MRI scan with a size of least 3 mm, at least one of which being cerebral, ovoid, or periventricular, * Willing to participate and to sign informed consent. * \- HEALTHY CONTROLS * Men and Women, * Age 18-60years, * Native French language, * Willing to participate and to sign informed consent. Exclusion Criteria: * \- PATIENTS: * Prior documented neurological episode suggestive of MS, * History of neurological disease and/or other neurological diseases, * Psychiatric diseases, * Known chronic systemic diseases as judged by the investigator, * Alcohol or other addiction to toxic, * Disabling visual or motor problems preventing participation to neuropsychological assessments, * Acquisition disorders : Dyslexia, Dysphasia, Dyscalculia and dyspraxia, * Dosage change, stop or start of hypnotic or anxiolytic or antidepressive treatment less than 30 days, * Contra-indication to MRI (pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments or foreign objects in the eyes, skin or body, claustrophobia), * Steroid treatment less than one month (be taken orally or by infusion) at the dosage of 500mg daily, * Illiteracy, is unable to count or to read, * Pregnant or breastfeeding women, * Patient concerned by articles L 1121-5 to L 1121-8 (persons deprived of their liberty by a judicial or administrative decision, minors, persons of legal age who are the object of a legal protection measure or unable to express their consent). * \- HEALTHY CONTROLS * History of neurological disease and/or neurological diseases, * Psychiatric diseases, * Known chronic systemic diseases as judged by the investigator, * Alcohol or other addiction to toxic, * Acquisition disorders: Dyslexia, Dysphasia, Dyscalculia and dyspraxia, * Known cognitive impairment or Prior neuropsychological testing with the same tests less than one year, * Hypnotic or anxiolytic or antidepressive treatment, * Steroid treatment less than one month (be taken orally or by infusion) at the dosage of 500mg daily, * Contra-indication to MRI (pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments or foreign objects in the eyes, skin or body, claustrophobia) or refusing MRI, * Illiteracy, unable to count or to read, * Pregnant or breastfeeding women, * Patient concerned by articles L 1121-5 to L 1121-8 (persons deprived of their liberty by a judicial or administrative decision, minors, persons of legal age who are the object of a legal protection measure or unable to express their consent).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple sclerosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • CHU de Bordeaux - service de neurologie

    Bordeaux, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.